Solid-state transformation of different gabapentin polymorphs upon milling and co-milling

被引:58
作者
Lin, Shan-Yang [1 ]
Hsu, Cheng-Hung [2 ]
Ke, Wen-Ting [2 ]
机构
[1] Yuanpei Univ, Lab Pharm Biopharm, Dept Biotechnol, Hsinchu, Taiwan
[2] Orient Pharma Co Ltd, Dept Res & Dev, Tao Yuan, Taiwan
关键词
Gabapentin; Milling; Co-milling; Polymorphic transition; Additives; ENHANCE DISSOLUTION; THERMAL-BEHAVIOR; MICRONIZATION; NANOPARTICLES; INDOMETHACIN; FAMOTIDINE; PREDICTION; MECHANISM;
D O I
10.1016/j.ijpharm.2010.06.014
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The purpose of this study was to investigate the milling effect on the polymorphic transformation of four gabapentin (GBP) Forms I-IV in the absence of additive Four polymorphs of GBP were previously prepared and identified, in which the GBP Form I was proven to be a monohydrate, but other GBP Forms II-IV belonged to anhydrate. The GBP Form II was the most stable polymorph available in the market The co-milling process affecting the polymorphic stability of GBP Form II with different additives was also examined. During the 120-min-milling or co-milling course, the milled sample was withdrawn at prescribed intervals for Fourier transform infrared (FTIR) microspectroscopic determination In the absence of additive, each polymorph of GBP exhibits a different polymorphic transformation behavior in the 120-mm-milling course. The results indicate that GBP Form I was previously dehydrated and transited to Form II, GBP Form II was first transformed to Form III and then changed to Form IV: GBP Form III was previously transited to Form II, then changed to Form III and transformed to Form IV at last; whereas GBP Form IV was first changed to Form II, then transited to Form III and finally to Form IV It was clearly evidenced that if GBP Form III or IV appeared in the milled mixture a little amount of GBP-lactam was certainly detected. In the presence of additives, there was almost lack of polymorphic transition for GBP Form II by co-milling GBP Form II with Emcompress, beta-cyclodextrin, mannitol. corn starch or magnesium stearate. By co-milling GBP Form II with Avicel, dextrin, hydroxypropyl beta-cyclodextrin, hydroxypropyl methylcellulose, Kollidon K-30 or gelatin, GBP Form II was transformed to Form IV alone On the other hand, the GBP Form IV and a little amount of GBP-lactam were also found in the co-milled mixture after co-milling with GBP Form II with Aerosil or talc. This reveals that the solid-state transformation of GBP Form II after co-milling was markedly dependent on the types of additive used. (C) 2010 Elsevier B V All rights reserved
引用
收藏
页码:83 / 90
页数:8
相关论文
共 44 条
[31]   Cogrinding as a Tool to Produce Sustained Release Behavior for Theophylline Particles Containing Magnesium Stearate [J].
Nokhodchi, Ali ;
Okwudarue, Ononuju N. ;
Valizadeh, Hadi ;
Momin, Mohammad N. .
AAPS PHARMSCITECH, 2009, 10 (04) :1243-1251
[32]  
OGUCHI T, 2004, J PHARM SCI TECHNOL, V64, pS59
[33]  
PESACHOVICH M, 2001, Patent No. 6255526
[34]   Improvement of water solubility and in vitro dissolution rate of aceclofenac by complexation with β-cyclodextrin and hydroxypropyl-β-cyclodextrin [J].
Ranpise, Nisharani S. ;
Kulkarni, Nilesh S. ;
Mair, Parth D. ;
Ranade, Arad N. .
PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, 2010, 15 (01) :64-70
[35]   Micron-size drug particles:: Common and novel micronization techniques [J].
Rasenack, N ;
Müller, BW .
PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, 2004, 9 (01) :1-13
[36]   Polymorphs of gabapenitin [J].
Reece, Hayley A. ;
Levendis, Demetrius C. .
ACTA CRYSTALLOGRAPHICA SECTION C-CRYSTAL STRUCTURE COMMUNICATIONS, 2008, 64 (03) :O105-O108
[37]   The mechanisms of action of gabapentin and pregaballin [J].
Sills, GJ .
CURRENT OPINION IN PHARMACOLOGY, 2006, 6 (01) :108-113
[38]   Crystalline solids [J].
Vippagunta, SR ;
Brittain, HG ;
Grant, DJW .
ADVANCED DRUG DELIVERY REVIEWS, 2001, 48 (01) :3-26
[39]   Thermal behavior and thermal decarboxylation of 10-hydroxycamptothecin in the solid state [J].
Wang, Shun-Li ;
Lin, Shan-Yang ;
Hsieh, Tzu-Feng ;
Chan, Shun-An .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2007, 43 (02) :457-463
[40]   Comparison between polyvinylpyrrolidone and silica nanoparticles as carriers for indomethacin in a solid state dispersion [J].
Watanabe, T ;
Hasegawa, S ;
Wakiyama, N ;
Kusai, A ;
Senna, M .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2003, 250 (01) :283-286